RareCyte Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
64
- Latest Deal Type
-
Debt
- Investors
-
11
RareCyte General Information
Description
Developer of precision biology products intended to detect circulating tumor cells. The company designs, manufactures, and markets worldwide end-to-end integrated platforms that provide advances in discovery, translational, and future clinical markets, enabling medical researchers to monitor circulating tumor cell counts and biomarker expression over time for clinical research.
Contact Information
Website
www.rarecyte.comCorporate Office
- 2601 Fourth Avenue
- Suite 500
- Seattle, WA 98121
- United States
Corporate Office
- 2601 Fourth Avenue
- Suite 500
- Seattle, WA 98121
- United States
RareCyte Timeline
RareCyte Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Debt - General | 01-Apr-2026 | Completed | Generating Revenue | |||
| 12. Grant | 21-Aug-2025 | Completed | Generating Revenue | |||
| 11. Later Stage VC | 21-Nov-2024 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series H) | 25-Jul-2023 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series G) | 09-Sep-2021 | Completed | Generating Revenue | |||
| 8. Debt - PPP | 13-Apr-2020 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series F) | 19-Dec-2019 | Completed | Generating Revenue | |||
| 6. Debt - General | 06-Jul-2018 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series E) | 22-May-2018 | $5M | $53M | Completed | Generating Revenue | |
| 4. Later Stage VC (Series D) | 26-Jul-2017 | $16M | $48M | Completed | Generating Revenue |
RareCyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series H | ||||||||
| Series G | ||||||||
| Series F | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 1,500,000 | $0.000010 | $2.5 | $2.5 | 1x | $2.5 | 0.41% | |
| Series A | 3,200,000 | $0.000010 | $1.64 | $1.64 | 1x | $1.64 | 0.88% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
RareCyte Comparisons
Industry
Financing
Details
RareCyte Competitors (39)
One of RareCyte’s 39 competitors is Epigenomics, a Formerly VC-backed company based in Heidelberg, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Epigenomics | Formerly VC-backed | Heidelberg, Germany | ||||
| Foundation Medicine | Formerly VC-backed | Boston, MA | ||||
| Exosomics | Venture Capital-Backed | Siena, Italy | ||||
| ROCA Test | Formerly VC-backed | Cambridge, United Kingdom | ||||
| Viatar CTC Solutions | Formerly VC-backed | Lowell, MA |
RareCyte Patents
RareCyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260072261-A1 | Transmitted light microscopy systems and methods of use | Pending | 06-Sep-2024 | ||
| US-12038381-B1 | Methods of reducing spectral crosstalk in multiplexed fluorescence imaging | Active | 18-Aug-2023 | ||
| WO-2025042409-A1 | Methods of reducing spectral crosstalk in multiplexed fluorescence imaging | Inactive | 18-Aug-2023 | ||
| AU-2020440916-A1 | Optical trains for imaging systems and spectral edge detection | Pending | 06-Apr-2020 | ||
| CA-3174791-A1 | Optical trains for imaging systems and spectral edge detection | Pending | 06-Apr-2020 | G02B21/16 |
RareCyte Signals
RareCyte Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gates Foundation | Not-For-Profit Venture Capital | |||
| GKCC | Venture Capital | Minority | ||
| Sheatree Capital | Venture Capital | Minority | ||
| The Forest Road Company | VC-Backed Company | Minority | ||
| Agilent Technologies | Corporation | Minority |
RareCyte FAQs
-
When was RareCyte founded?
RareCyte was founded in 2009.
-
Where is RareCyte headquartered?
RareCyte is headquartered in Seattle, WA.
-
What is the size of RareCyte?
RareCyte has 64 total employees.
-
What industry is RareCyte in?
RareCyte’s primary industry is Diagnostic Equipment.
-
Is RareCyte a private or public company?
RareCyte is a Private company.
-
What is RareCyte’s current revenue?
The current revenue for RareCyte is .
-
How much funding has RareCyte raised over time?
RareCyte has raised $130M.
-
Who are RareCyte’s investors?
Gates Foundation, GKCC, Sheatree Capital, The Forest Road Company, and Agilent Technologies are 5 of 11 investors who have invested in RareCyte.
-
Who are RareCyte’s competitors?
Epigenomics, Foundation Medicine, Exosomics, ROCA Test, and Viatar CTC Solutions are some of the 39 competitors of RareCyte.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process